Status: Recruiting
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients suffering from resistant systemic lupus erythematosus can tolerate.
Participants needed: 75
Trial details
Phase: Phase 1, Phase 2Age: 18-90Biological sex: AllType: InterventionalSponsor: Essen BiotechUpdated: Oct 15, 2024Locations: 1
Eligibility criteria
18-90 years old; [+13]
Renal disease: severe lupus nephritis (serum creatinine > 2.5 mg/dL or 221 μmol/... [+16]